期刊
JOURNAL OF DERMATOLOGY
卷 -, 期 -, 页码 -出版社
WILEY
DOI: 10.1111/1346-8138.17082
关键词
adverse event; BRAF/MEK inhibitor; HLA-DRB1*04; melanoma; VKH disease-like uveitis
类别
The combination of BRAF kinase inhibitors and MEK kinase inhibitors may lead to severe VKH disease-like uveitis in melanoma patients with the HLA-DRB1*04 haplotype.
The combination of BRAF kinase inhibitors (BRAFis) and MEK kinase inhibitors (MEKis) is one of the most promising chemotherapy regimens in the treatment of BRAF-mutant melanoma. Although BRAFi plus MEKi combined therapy is widely used for the treatment of BRAF(V600)-mutated melanoma, the incidence of uveitis caused by BRAFi plus MEKi is limited. In this report, we described five cases (two men and three women) of Vogt-Koyanagi-Harada (VKH) disease-like uveitis in melanoma patients who received BRAFi plus MEKi combined therapy. Of note, all the patients had the HLA-DRB1*04 haplotype, which is frequently detected in VKH-like non-infectious uveitis. On the other hand, among BRAFi plus MEKi-treated patients who did not develop VKH disease-like uveitis, only one of five (20%) patients had the HLA-DRB1*04 haplotype. Collectively, BRAFi/MEKi might induce severe VKH disease-like uveitis in melanoma patients with the HLA-DRB1*04 haplotype.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据